Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide

Journal of Chemotherapy

Volumn 11, Issue 2, 1999, Pages 144-149

  Polyzos, A ^a   Tsavaris, N ^b   Kosmas, C ^b   Petrikos, G ^a   Giannikos, L ^b   Kalahanis, N ^b   Papadopoulos, O ^b   Christodoulou, K ^b   Giannakopoulos, K ^b   Veslemes, M ^a   Katsilambros, N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Carboplatin; Cisplatin; Cyclophosphamide; Ifosfamide; Ovarian cancer; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; ONDANSETRON;

ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEUROTOXICITY; OVARY CANCER; SECOND LOOK SURGERY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR RECURRENCE;

EID: 0032921433     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1999.11.2.144     Document Type: Article

References (30)

1. 1 Hainsworth JD, Grosh WW, Burnett LS, et al. Advanced ovarian cancer: Long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165-170.
2. 2 Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens. (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157-1168.
3. 3 Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 457-465.
4. 4 Louie KG, Ozols RF, Myers CE, et al. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986; 4: 1579-1585.
5. 5 McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-279.
6. 6 Surwit EA, Alberts DS, O'Tolle RV, et al. Phase II trial of vinblastine in previously treated patients with ovarian cancer: A Southwest Oncology Group study. Gynecol Oncol 1987; 27: 214-219.
7. 7 Pater JL, Carmichael JA, Krepart GV, et al. Second-line chemotherapy of stage III-IV ovarian carcinoma: A randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep 1987; 71: 277-281.
8. 8 Chambers SK, Chambers JT, Kohorn EI, et al. Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. Gynecol Oncol 1987; 27: 233-240.
9. 9 Osborne RJ, Harvey VJ, Slevin ML, et al. Phase II study of vinblastine and bleomycin in advanced ovarian cancer. Cancer Treat Rep 1987; 71: 335-336.
10. 10 Ifosfamide and mesna. Med Lett Drugs Ther 1989; 31: 98-99.
11. 11 Thigpen T, Vance R, Lambuth B, et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 1987; 60: 2104-2116.
12. 12 Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1672-1676.
13. 13 Markman M, Rothman R, Hakes T, et al. Second-line cisplatin treatment in patient with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
14. 14 Markman M, Hakes T, Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer. Activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243-248.
15. 15 Goldin A. Ifosfamide in experimental tumors systems. Semin Oncol 1982; 9: 14-18.
16. 16 Tenfel G, Pfleiderer A. Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas. Geburts Franen Heilk 1976; 36: 274-278.
17. 17 World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, 1979.
18. 18 Kaplan HL, Meier R. Non-parametric estimations from incomplete observations. J Am Stat Assoc 1958; 53: 457-459.
19. 19 Dixon WS, Massey FJ Jr. Introduction to statistical analysis. 4th edition, New York, McGraw-Hill, 1983.
20. 20 Bruhl P, Gunther U, Hoefer-Janker P. Results obtained with fractionated ifosfamide massive dose treatment in generalized malignant tumors. Int Clin Pharmacol 1976; 14: 29-32.
21. 21 Sorensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995; 56: 75-78.
22. 22 Green JA, Slater AJ. A study of cis-platin and ifosfamide in alkylating agent resistant ovarian cancer. Gynecol Oncol 1989; 32: 233-236.
23. 23 Marzola M, Parma G, Bonazzi C et al. Salvage therapy with ifosfamide and mitoxantrone in advance ovarian cancer. Ann Oncol 1996; 7: 419-21.
24. 24 Advanced epithelial ovarian cancer: 1993 consensus statements. Ann Oncol 1993; (4) Supp: 83.
25. 25 Colombo N, Marzola M, Parma G et al. Paclitaxel vs. CAP (cyclophosphamide, adriamycin, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study. Proc ASCO 1996; 15: 279.
26. 26 Pucci F, Bella M, Salvagni S et al. Paclitaxel and ifosfamide in heavily pretreated patients with advanced ovarian cancer. Proc ASCO 1996; 15: 301.
27. 27 Klaassen U, Harstrick A, Stahl M et al. Paclitaxel and ifosfamide in pretreated patients with advanced ovarian carcinoma. Proc ASCO 1996; 15: 295.
28. 28 Dimopoulos MA, Papadimitriou C, Gennatas C et al. Ifosfamide and paclitaxel chemotherapy for advanced epithelial ovarian cancer. Ann Oncol 1997; 8: 195-197.
29. 29 De Lena M, Bottalico C, Brandi M, et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with patinum. J Clin Oncol 1997; 15: 3208-3213.
30. 30 Trigpen JT, Blessing JA, Ball H et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-1753.